Bayer's Retinal Pioneers Programme

Established in 2018, Retinal Pioneers is a promotional programme organised and funded by Bayer, designed to contribute towards the evolution of retinal knowledge and catalyse innovation in medical retina. As part of the programme, this Retinal Pioneers Hub provides a source of on-demand, educational resources developed in collaboration with national and international thought leaders in ophthalmology. Materials on this hub are available throughout the year, with new content released quarterly.

Retinal Pioneers Summit (RPS)

The Retinal Pioneers Summit is an annual meeting designed to enable UK ophthalmologists to explore the latest innovations and scientific and clinical advancements in the management of medical retina conditions.

EYLEA (aflibercept) 8 mg: Real-world insights from US and UK clinicians

These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg in clinical practice for licensed indications. Each video includes early experiences and key learnings from real-world cases, designed to aid understanding and help facilitate best practice for EYLEA 8 mg in UK clinical practice.

Key developments relating to EYLEA (aflibercept) 8 mg

Eye on the Horizon podcast series

Episode 7: Laughing through Life: Coping Mechanisms and Advice for Students (NEW!)

Listen to the seventh episode in this podcast series, in which Peter Cackett (Consultant Ophthalmologist, NHS Lothian) and guest speaker Will Flanary (American Ophthalmologist and Comedian, AKA Dr Glaucomflecken) discuss how Will has used humour as a coping mechanism throughout challenges in his life and how he transitioned between medicine and stand-up comedy, and most recently social media influencer.

Previous episodes can also be accessed by following the links below.

Challenging cases in medical retina

These case study posters feature challenging scenarios across multiple indications in medical retina, provided by a range of clinicians from across the UK. Each poster includes key information from one or two short case studies and invites you to reflect on the steps that you would follow to manage the same cases.

Resources exploring developments and key principles central to medical retina

Talking head video series with Dr SriniVas Sadda: Advances in imaging technologies

Imaging expert Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA, explores advances in imaging in medical retina in this talking head video series. In each 10-minute video, Dr Sadda provides a detailed overview of a different imaging technology, including its advantages and disadvantages, as well as its practicalities in clinical practice.

Abbreviations

AMD, age-related macular degeneration. DMO, diabetic macular oedema. FLIO, Fluorescence Lifetime Imaging Ophthalmoscopy. HCP, healthcare professional. nAMD, neovascular age-related macular degeneration. NHS, National Health Service. OCT, optical coherence tomography. Q16, every 16 weeks. RVO, retinal vein occlusion. SEL DESP, South East London Diabetic Eye Screening Programme. T&E, treat-and-extend. UCLA, University of California, Los Angeles. VEGF, vascular endothelial growth factor.

Footnotes

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO). For full details please refer to Summary of Product Characteristics.

*After 3 initial doses, the EYLEA 2 mg treatment interval is extended to 2 months. The treatment interval can then be further extended up to 16 weeks, using proactive T&E dosing.

Prescribing information for EYLEA® (aflibercept) can be found here.